You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE backs Rinvoq for moderate active RA

AbbVie has announced that its oral therapy Rinvoq (upadacitinib) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for the treatment of moderate active rheumatoid arthritis (RA).